TG Therapeutics sells BRIUMVI, an infused anti-CD20 antibody for relapsing multiple sclerosis that competes with Ocrevus and Kesimpta, and is developing a subcutaneous version.
TG's investment case rests on growing approved BRIUMVI sales and adding subcutaneous dosing. U.S. net product revenue reached $227.7 million in the second quarter 2026. Fully enrolled subcutaneous Phase 3 has topline expected year-end 2026 or early 2027; supportive exposure estimates remain Phase 1 modeling. ENHANCE supports simpler IV initiation. Cash, investments and projected sales support management's operating plan. Initial azer-cel results in progressive MS add a longer-term opportunity, with small patient numbers and short follow-up limiting conclusions.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Subcutaneous BRIUMVI matches IV exposure
Does quarterly subcutaneous BRIUMVI achieve non-inferior drug exposure versus IV with acceptable tolerability?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
BRIUMVI growth supports expansion; subcutaneous pivotal results remain the next clinical decision
BRIUMVI's commercial momentum and label-optimization pipeline test whether a third anti-CD20 can sustain share against Ocrevus and Kesimpta at scale
BRIUMVI's commercial momentum and label-expansion pipeline hinge on whether subcutaneous and consolidated-dosing data unlock new share and indications against entrenched anti-CD20s
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases, Neurology and pain, Psychiatric disorders, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
13 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.